Ask AI

Gastrointestinal Cancers

Share

Program Content

Activities

  • ANCHOR
    ANCHOR: Phase III Trial of Anlotinib or Bevacizumab With 1L Chemotherapy for RAS/BRAF Wild-Type Unresectable mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • ATOMIC
    ATOMIC: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab in Patients With Stage III Deficient DNA Mismatch Repair Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • BREAKWATER
    BREAKWATER: PFS From the Phase III Trial of 1L Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • MATTERHORN
    MATTERHORN: Phase III Trial of Durvalumab or Placebo + FLOT in Resectable Gastric and Gastroesophageal Junction Cancers
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • DESTINY Gastric04
    DESTINY-Gastric04: T-DXd vs Ramucirumab + Paclitaxel as Second-line Therapy in HER2+ Unresectable/Metastatic Gastric Cancer/GEJ Adenocarcinoma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • DYNAMIC III
    DYNAMIC-III: ctDNA-Guided Escalation of Adjuvant Chemotherapy vs Standard Management in Stage III Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • CheckMate 577 OS
    CheckMate 577: Final OS Analysis of Adjuvant Nivolumab vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • CodeBreaK 101 Cohort G
    CodeBreaK 101 Cohort G: Sotorasib + Panitumumab and FOLFIRI in Previously Treated KRAS G12C–Mutated mCRC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2025

    Expires: December 04, 2025

  • CASSANDRA
    CASSANDRA PACT-21: Randomized, Phase III Trial of Preoperative Chemotherapy With mFOLFIRINOX or PAXG for Stage I-III PDAC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2025

    Expires: December 08, 2025

  • CheckMate 8HW Update
    CheckMate 8HW: Expanded Analyses in Patients With Centrally Confirmed MSI-H/dMMR mCRC From the Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab or Chemotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2025

    Expires: December 08, 2025

  • GAIN
    GAIN: Phase III Trial of (Neo)Adjuvant Chemotherapy and Radical Liver Resection vs Radical Liver Resection Alone ± Adjuvant Therapy in BTC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2025

    Expires: December 08, 2025

  • ctDNA and Stage III Colon Cancer Prognosis
    Phase III N0147 Substudy: Relationship Between Postoperative ctDNA and Patient Outcomes After FOLFOX-Based Adjuvant Therapy for Stage III Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2025

    Expires: December 08, 2025

  • POLCAGB
    POLCAGB: Phase II/III Trial of Neoadjuvant Chemotherapy vs Neoadjuvant Chemoradiotherapy in Locally Advanced Gallbladder Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2025

    Expires: December 09, 2025

  • CT041 ST 01
    CT041-ST-01: Randomized Phase II Study of Satri-cel vs Physician’s Choice Treatment for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2025

    Expires: December 09, 2025

  • 1801 Part 3B Ph II of Elraglusib
    1801 Part 3B: Preliminary Results From a Phase II Study of Elraglusib + Gemcitabine/nab-Paclitaxel (GnP) vs GnP in Previously Untreated mPDAC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2025

    Expires: December 10, 2025

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group